Licensing status

Publication and contact information

Drug delivery

Lipid nanoparticle formulation of self-amplifying RNAs for vaccination

Self-amplifying RNA presented in a lipid nanoparticle formulation could be a viable nonviral alternative to viral delivery-based RNA vaccination technologies. In mice and rats, intramuscular injection of a lipid nanoparticle-encapsulated, self-amplifying RNA (LNP/RNA) encoding the RSV F protein had immunogenicity comparable to injection of viral replicon particles. In cotton rats challenged with respiratory syncytial virus (RSV), prophylactic vaccination with the RSV F protein-encoding LNP/RNA provided protection comparable to that of vaccination with viral replicon particles. Ongoing studies include testing the LNP/RNA platform in larger animals.

SciBX 5(36); doi:10.1038/scibx.2012.966
Published online Sept. 13, 2012

Patent applications filed; unlicensed

Geall, A.J. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 20, 2012;
Contact: Andrew J. Geall, Novartis Vaccines and Diagnostics, Cambridge, Mass.